Uveal melanoma is a very aggressive type of melanoma that affects the eye. It is a rare disorder, affecting an estimated 2,500 people in the United States each year. However, nearly half of uveal melanoma patients will develop ...
Jul 8, 2019
0
916
With more targeted therapies being approved each year for cancer, the development of drug resistance to these agents is a growing concern. It has often been assumed that drug resistance is due to the presence or development ...
May 15, 2019
0
14
The protein BRAF is a key player in the development of many different types of cancer, including melanoma. Scientists have known that BRAF becomes activated by growth factors and subsequently stimulates downstream proteins ...
Apr 24, 2019
0
8
Melanoma is one of the most aggressive types of skin cancer, but recent advances in targeted therapies have improved the prognosis for many patients. Unfortunately, for some patients these positive outcomes are not long lasting, ...
Apr 15, 2019
0
3
Cancer is a highly varied disease, with genetic differences among different tumor types, individuals and ancestral populations. These genetic differences can impact disease aggressiveness, the type of disease, and the response ...
Apr 5, 2019
0
4
The immune system is an important defender against cancer. Immune cells continuously search the body for disease and use their anti-tumor cell properties to target and destroy defective cells. However, most cancer patients ...
Apr 4, 2019
0
30
The scientific community has made great strides over the past decade in the development of a new class of cancer therapy called immunotherapy, a treatment that activates a patient's own immune system to target cancer cells. ...
Feb 14, 2019
0
38
Chimeric antigen receptor T-cell therapy, or CAR T, was named the 2017 Advance of the Year by the American Society of Clinical Oncology. The FDA approved two CAR T products last year for treatment of adult large B-cell lymphoma ...
Dec 3, 2018
0
1
A new article published today in The Lancet Oncology shows 39 percent of large B cell lymphoma patients treated with the chimeric antigen receptor T-cell therapy (CAR T) Yescarta (axicabtagene ciloleucel) remained in remission ...
Dec 3, 2018
0
1
Prostate cancer is the second most common cancer in American men. But black men bear a disproportionate burden of its effects. It's more common—and more than twice as deadly—among black men compared to their white counterparts. ...
Oct 2, 2018
0
2
